Brenda Dauer

Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy

Fiona Lampe, José M. Gatell, Schlomo Staszewski et al. · Archives of Internal Medicine · 2006 · 91 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

Christoph Stephan, Nils von Hentig, Irene S. Kourbeti et al. · AIDS · 2004 · 50 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

Nils von Hentig, Brenda Dauer, Annette Haberl et al. · European Journal of Clinical Pharmacology · 2007 · 40 citations

Medicine, Pharmacokinetics, Pharmacology +14

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy

Schlomo Staszewski, Errol Babacan, Christoph Stephan et al. · Journal of Antimicrobial Chemotherapy · 2006 · 33 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1???Positive Individuals

Colette Smith, Schlomo Staszewski, Caroline Sabin et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 29 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17